Experimental treatment kills prostate tumor cells while reawakening antitumor immunity

Key Points:

• Engineered ultrasmall fluorescent core-shell silica nanoparticles (C’ dots) targeted to prostate tumors effectively induce tumor cell death and enhance antitumor immune responses in aggressive prostate cancer mouse models, leading to several complete remissions.
• The nanoparticles trigger ferroptosis, a self-destruct process in tumor cells involving oxidative degradation of cell membranes, while converting the tumor immune microenvironment from inactive ("cold") to highly active ("hot"), improving responses to immunotherapies.
• Combining C’ dots with immune checkpoint blockade and CSF-1R blockade immunotherapies synergistically resulted in complete or near-complete tumor remissions and extended survival in up to half of treated mice, showing promise for durable treatment effects.
• The nanoparticles are selectively targeted to prostate cancer cells via PSMA, show no toxicity in non-tumor tissues, and disrupt tumor metabolism and immune suppression without harming healthy cells.
• Researchers plan to advance these silica nanoparticles into clinical trials as a novel therapeutic approach that integrates direct tumor killing with immune and metabolic modulation, potentially overcoming current limitations in prostate cancer immunotherapy.